leadf
logo-loader
viewFaron Pharmaceuticals Oy

Faron Pharma right in middle of fight against cancer and coronavirus

Snapshot

  • Focuses on Clevegen and Traumakine
  • Clevegen in studies for several types of cancer
  • Traumakine being tested as a treatment for coronavirus in three trials
cancer

Quick facts: Faron Pharmaceuticals Oy

Price: 322.5 GBX

AIM:FARN
Market: AIM
Market Cap: £162.6 m
Follow

What it does

Faron Pharmaceuticals Oy (LON:FARN)(NASDAQFIRSTNORTH:FARON) is a Finnish drug discovery firm focusing on two programmes: Clevegen and Traumakine.

Clevegen

Immunotherapy treatment Clevegen is in a phase I/II trial (MATINS) for metastatic cutaneous melanoma as well as hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers.

Tumour cells are adept at creating a shield around themselves to evade detection by the immune system, therefore staving off destruction.

Clevegen has been designed to recognise cancer and break the tumour's protective shell.

The treatment is an anti-Clever-1 antibody which causes changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive macrophages to immune active macrophages.

Ultimately, if it is successful, this new breed of treatment will be used in combination with PD-1 inhibitors to tackle the killer disease.

Faron was also given the green light to broaden the scope of its phase I/II cancer trial after a review of the interim data.

The MATINS study of the immunotherapy Clevegen will now take in seven further strains of the disease besides the two already assessed - colorectal and ovarian.

The generic name is bexmarilimab.

 

Traumakine

In January, Faron said the US Food & Drug Administration (FDA) has approved the phase II/III trial to combat the acute symptoms of coronavirus (COVID-19).

Traumakine, an intravenous interferon beta-1a drug, will be given to people who have been hospitalised but who do not yet need ventilation. It will be administered before corticosteroids are given.

The aim is to prevent systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) – and by extension improve sufferers’ condition and reduce the death rate among patients.

“IFN beta-1a has previously demonstrated a compelling scientific rationale as the body's first line of defence against viral infections and might be advantageous over current standard of care when given intravenously to patients suffering from COVID-19 induced ARDS,” said Faron chief executive Dr Markku Jalkanen in a statement.

 

What the boss says: Markku Jalkanen, chief executive

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Oy named herein, including the promotion by the Company of Faron Pharmaceuticals Oy in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE gains on hopes UK Covid-19 restrictions might be lifted...

The Market Report with Katie Pilbeam. FTSE 100 made good progress on hopes that UK Covid-19 restrictions might be lifted early as infection rates have started to fall.  Hospitality groups were to the fore as London’s blue-chip index added 40 to 6,679.   A row has blown up between...

on 26/1/21

2 min read